Amplia Therapeutics develops focal adhesion kinase (FAK) inhibitors for cancer and fibrosis, led by narmafotinib. Company news centers on clinical development of narmafotinib in fibrotic cancers, including pancreatic and ovarian cancer, where updates describe combination studies with standard-of-care chemotherapy, trial data presentations, safety and response analyses, and biomarker work.
Recurring announcements also cover preclinical research in KRAS-mutated cancer models, GMP manufacturing and drug-supply scale-up for narmafotinib, patent and regulatory communications, quarterly activities and cash-flow reporting, and the company’s ASX listing and OTCQB quotation under INNMF.
Amplia Therapeutics (OTCQB:INNMF) has entered a Clinical Trial Collaboration & Supply Agreement with Eli Lilly to evaluate Amplia’s investigational FAK inhibitor narmafotinib (AMP945) with Lilly’s late‑stage investigational KRAS G12C inhibitor olomorasib in a Phase 1b/2b trial for second‑line advanced non‑small cell lung cancer (NSCLC).
According to Amplia, it will conduct the study, planned to start in late 2026 at sites in Australia and the USA, while Lilly will provide in‑kind supply of olomorasib. The collaboration extends narmafotinib development beyond pancreatic and ovarian cancer into NSCLC, targeting KRAS G12C‑mutant disease and building on Amplia’s ACCENT pancreatic trial data showing a 36% response rate, 11.1‑month median overall survival and 7.8% complete responses in combination with chemotherapy.
Amplia Therapeutics (ASX:ATX, OTCQB:INNMF) reported that a scientific manuscript describing extensive preclinical studies of narmafotinib (AMP945) in pancreatic cancer models is now available on the bioRxiv server. The research, led by Professor Paul Timpson at the Garvan Institute of Medical Research, examines multiple mechanisms through which narmafotinib may affect pancreatic cancer.
Key findings include reduced tumour fibrosis, enhanced anti-tumour activity when combined with chemotherapy across several preclinical models, reduced metastatic spread in a metastatic model, and downregulation of genes linked to chemotherapy resistance. According to Amplia, this publication is among the most comprehensive preclinical evaluations of narmafotinib and supports its ongoing clinical trials in pancreatic and ovarian cancer.
Amplia Therapeutics (OTCQB:INNMF) announced publication of a new patent application for chemically novel focal adhesion kinase (FAK) inhibitors. The filing expands its FAK intellectual property and, if granted, could protect the new molecules and their use until 2046.
The application covers compounds related to lead drug narmafotinib, which is in clinical trials for pancreatic and ovarian cancer, and complements preclinical candidate AMP886, broadening Amplia’s pipeline and potential future development and partnering options.
Amplia Therapeutics (OTCQB: INNMF, ASX: ATX) appointed Mr Brett Carter as a non-executive director, effective 6 July 2026. Carter has over 25 years’ global biopharmaceutical experience spanning oncology drug development, corporate strategy and business development.
His background includes senior roles at GSK, leadership of Cancer Therapeutics CRC where Amplia’s assets were discovered, and involvement in an oncology licensing deal with Pfizer valued up to $670 million.
Amplia Therapeutics (OTCQB:INNMF, ASX:ATX) announced board leadership changes as part of a renewal and succession plan. Dr Warwick Tong will retire as Board Chair on 30 June 2026 and continue as a Non-Executive Director.
Ms Jane Bell AM, an Independent NED since April 2021 and current Audit and Risk Committee Chair, was unanimously appointed Board Chair effective 30 June 2026. According to Amplia, recent clinical trial success and growing interest in its portfolio provide a context for these changes.
Amplia Therapeutics (OTCQB:INNMF) outlined progress with its FAK inhibitor narmafotinib in pancreatic cancer and its potential combination with emerging KRAS inhibitors. ACCENT trial data showed a 35% response rate, interim median PFS of 7.7 months, OS of 11.1 months, and a 7.8% confirmed complete response rate.
Narmafotinib has FDA Fast Track and Orphan Drug designations, a registration-enabling Phase 2b study underway, and an ovarian cancer study planned with ANZGOG.
Amplia Therapeutics (OTCQB: INNMF, ASX: ATX) is initiating a Phase 2b, registration-enabling study of narmafotinib in advanced pancreatic cancer, using a new daily dosing regimen with gemcitabine and Abraxane.
The 12-patient first stage, run at 3-4 Australian sites, targets safety, tolerability, PK and efficacy, with enrolment expected by Q4 2026 and key assessments by Q2 2027. Narmafotinib holds FDA orphan drug and fast track designations.
Amplia Therapeutics (OTCQB:INNMF) and ANZGOG have agreed to an investigator-initiated clinical study (PRROSE) testing narmafotinib with carboplatin and paclitaxel in high-grade serous ovarian cancer patients who show poor response to up-front platinum chemotherapy.
The trial will enroll ~15–20 patients, focus on safety and whether narmafotinib increases eligibility for successful interval debulking surgery, and will collect extensive tissue and blood biomarkers.
Amplia Therapeutics (OTCQB:INNMF) presented mature data from the ACCENT trial in metastatic pancreatic cancer at AACR on April 22, 2026. The oral presentation reported a manageable toxicity profile and independent reads showing 5 confirmed CRs (8% of 64 patients), an overall response rate of 36%, a disease control rate of 70%, median OS 11.1 months and median PFS 7.7 months.
The company said subsequent trials will use daily narmafotinib dosing and plan a pivotal study based on ACCENT findings.
Amplia Therapeutics (OTCQB:INNMF) reported updated ACCENT Phase 1b/2a data in advanced pancreatic cancer showing a median overall survival (mOS) of 11.1 months and five confirmed complete responses (CRs) at the 400 mg narmafotinib dose, a CR rate of 7.8% (5/64).
Independent central RECIST 1.1 review raised CRs by four patients, updated ORR to 35.9% (23/64), found no additional toxicity, and the Company will present results at AACR April 17-22, 2026.